Are you Dr. Lee?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 34 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
10 Center Drive, Bldg10
Room12n226
Rockville, MD 20814Phone+1 301-443-7735Fax+1 212-932-5258
Summary
- Dr. Jung-Min Lee, MD is an oncologist in Rockville, Maryland. She is currently licensed to practice medicine in New York.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2008 - 2012
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 2003 - 2006
Certifications & Licensure
NY State Medical License 2007 - 2026- American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
- 6 citationsPulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab.Dante A. Suffredini, Jung-Min Lee, Cody J. Peer, Drew Pratt, David E. Kleiner
BMC Pulmonary Medicine. 2018-07-11 - 140 citationsDurvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II StudyAnish Thomas, Rasa Vilimas, Christopher Trindade, Rebecca A. Erwin-Cohen, Nitin Roper
Journal of Thoracic Oncology. 2019-08-01 - 145 citationsPrexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 ...Jung-Min Lee, Jayakumar R. Nair, Alexandra S Zimmer, Stanley Lipkowitz, Christina M. Annunziata
The Lancet. Oncology. 2018-02-01
Press Mentions
Pembrolizumab Improves Survival in Advanced Triple-Negative Breast CancerAugust 9th, 2022- The Power of Shared Purpose: Transforming Gynecologic Cancer CareMarch 26th, 2024
